Hualan's Subsidiary Invests 205 Million Yuan for 34.17% Stake in Natural Constant, Strategically Expanding into AI Pharma

Stock News06-01

Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. (ASX: 301093) has announced that its wholly-owned subsidiary, Hainan Lingqing Digital Intelligence Pharmaceutical Technology Co., Ltd., will use its own funds of 205 million yuan to invest in Wuxi Natural Constant Technology Co., Ltd. This capital increase will result in the subsidiary holding a 34.17% stake in Natural Constant on a fully diluted basis post-transaction.

This investment represents a forward-looking strategic move by the company into the AI pharmaceutical sector. The business model, technological pathways, and profit cycles in this field differ from those of the company's traditional core operations.

The company stated that its current operations are orderly and its financial structure remains robust. The investment, made with the company's own capital, is contingent on ensuring the continued development of its primary business and is not expected to impact normal production activities or cash flow.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156745269?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156745269","market":"sh","top_or_hot":-1,"title":"Hualan's Subsidiary Invests 205 Million Yuan for 34.17% Stake in Natural Constant, Strategically Expanding into AI Pharma","media":"Stock News","content":"<p>Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. (ASX: 301093) has announced that its wholly-owned subsidiary, Hainan Lingqing Digital Intelligence Pharmaceutical Technology Co., Ltd., will use its own funds of 205 million yuan to invest in Wuxi Natural Constant Technology Co., Ltd. This capital increase will result in the subsidiary holding a 34.17% stake in Natural Constant on a fully diluted basis post-transaction.<br><br>This investment represents a forward-looking strategic move by the company into the AI pharmaceutical sector. The business model, technological pathways, and profit cycles in this field differ from those of the company's traditional core operations.<br><br>The company stated that its current operations are orderly and its financial structure remains robust. The investment, made with the company's own capital, is contingent on ensuring the continued development of its primary business and is not expected to impact normal production activities or cash flow.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hualan's Subsidiary Invests 205 Million Yuan for 34.17% Stake in Natural Constant, Strategically Expanding into AI Pharma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHualan's Subsidiary Invests 205 Million Yuan for 34.17% Stake in Natural Constant, Strategically Expanding into AI Pharma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-01 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. (ASX: 301093) has announced that its wholly-owned subsidiary, Hainan Lingqing Digital Intelligence Pharmaceutical Technology Co., Ltd., will use its own funds of 205 million yuan to invest in Wuxi Natural Constant Technology Co., Ltd. This capital increase will result in the subsidiary holding a 34.17% stake in Natural Constant on a fully diluted basis post-transaction.<br><br>This investment represents a forward-looking strategic move by the company into the AI pharmaceutical sector. The business model, technological pathways, and profit cycles in this field differ from those of the company's traditional core operations.<br><br>The company stated that its current operations are orderly and its financial structure remains robust. The investment, made with the company's own capital, is contingent on ensuring the continued development of its primary business and is not expected to impact normal production activities or cash flow.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"","article_id":"1156745269","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156745269","pubTimestamp":1780320813,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. (ASX: 301093) has announced that its wholly-owned subsidiary, Hainan Lingqing Digital Intelligence Pharmaceutical Technology Co., Ltd., will use...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","301093":"华兰股份","09939":"开拓药业-B","ARTY":"ISHARES FUTURE AI & TECH ETF","BK1515":"抗疫概念","AGIX":"通用人工智能 ETF-AGIX","BK1161":"生物科技","AIPO":"Defiance AI and Power Infrastructure ETF","BK1574":"生物医药B类股","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK0239":"医药制造"},"translate_title":"华兰旗下2.05亿元入股自然常数34.17%股权战略布局AI Pharma","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"301093":1,"AIPO":1,"09939":1,"ARTY":1,"AGIX":1,"CHAT":1},"content_text":"Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. (ASX: 301093) has announced that its wholly-owned subsidiary, Hainan Lingqing Digital Intelligence Pharmaceutical Technology Co., Ltd., will use its own funds of 205 million yuan to invest in Wuxi Natural Constant Technology Co., Ltd. This capital increase will result in the subsidiary holding a 34.17% stake in Natural Constant on a fully diluted basis post-transaction.This investment represents a forward-looking strategic move by the company into the AI pharmaceutical sector. The business model, technological pathways, and profit cycles in this field differ from those of the company's traditional core operations.The company stated that its current operations are orderly and its financial structure remains robust. The investment, made with the company's own capital, is contingent on ensuring the continued development of its primary business and is not expected to impact normal production activities or cash flow.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156745269","isCrawlerRequest":true}